REG - Cambridge Cognition - Appointment of Nominated Adviser and Joint Broker

Cambridge Cognition HoldingsAnnouncement

24/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220324:nRSX8271Fa&default-theme=true

RNS Number : 8271F  Cambridge Cognition Holdings PLC  24 March 2022

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Appointment of Nominated Adviser and Joint Broker

 

Director Disclosures

 

Cambridge Cognition Holdings (AIM: COG), which develops and markets digital
solutions to assess brain health, is pleased to announce the appointment of
Panmure Gordon (UK) Limited ("Panmure Gordon") as the Company's Nominated
Adviser and Joint Broker with immediate effect.

 

The Company also announces the information in the Appendix below relating to
additional director disclosures under Schedule Two, Paragraph (g) of the AIM
Rules for Companies.

 

For further information, contact:

 Cambridge Cognition Holdings Plc             Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer       press@camcog.com (mailto:press@camcog.com)

 Steven Powell, Chairman
 Panmure Gordon (NOMAD and Joint Broker)      Tel: 020 7886 2500

 Freddy Crossley / Emma Earl / Mark Rogers    (Corporate Advisory)

 Rupert Dearden                               (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)       Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)       Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

Appendix

 

The Company announces the following information relating to directors'
disclosures pursuant to Schedule Two, paragraph (g) of the AIM Rules for
Companies. At the time of the appointment of Debra Leeves and Richard Bungay
to the Board of the Company on 1 July 2019 and 14 September 2020 respectively,
the below disclosures were omitted:

 

Debra Leeves, Non-executive Director of the Company, held the following
previous directorships within five years of her appointment to the Board of
the Company:

-      REX Bionics Europe Limited

-      Radcliffe Academy Trust

 

Richard Bungay, Non-executive Director of the Company, was appointed a
director of Glide Pharmaceutical Technologies Limited ("Glide") on 1 July
2014. On 31 August 2017, Lindsey Cooper and David Ronald Taylor of RSM
Restructuring Advisory LLP were appointed as joint administrators of Glide
Pharmaceutical Technologies Limited. A notice of progress report to 7 March
2018 and filed on 15 March 2018 indicated all unsecured creditor balances had
been settled.  The company was subsequently dissolved following liquidation
on 20 October 2018.

 

Richard Bungay is also currently a director of the following companies:

-      Diurnal Limited

-      Macrotarg Limited

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPEAPDDAANAEFA